Valuation: Insmed Incorporated

Market Cap 2.51TCr 2.19TCr 2.02TCr 1.87TCr 3.54TCr 2,39000Cr 3.6TCr 24TCr 9.49TCr 1,17700Cr 9.41TCr 9.2TCr 4,04800Cr P/E 2026 *
-44.3x
P/E 2027 * 226x
Enterprise Value 2.45TCr 2.14TCr 1.98TCr 1.83TCr 3.46TCr 2,33600Cr 3.52TCr 24TCr 9.27TCr 1,15100Cr 9.2TCr 9TCr 3,95600Cr EV / Sales 2026 *
14.5x
EV / Sales 2027 * 8.8x
Free-Float
99.48%
Yield 2026 *
-
Yield 2027 * -
1 day-2.24%
1 week+3.59%
Current month+8.43%
1 month+25.83%
3 months-25.32%
6 months-34.30%
Current year-33.57%
1 week 108.55
Extreme 108.55
119.54
1 month 93.92
Extreme 93.92
119.54
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 20.01
Extreme 20.01
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 10/09/2012
Director of Finance/CFO 45 31/01/2020
Chief Tech/Sci/R&D Officer 62 19/12/2019
Director TitleAgeSince
Chairman 75 16/06/2009
Chairman 57 08/11/2018
Director/Board Member 72 29/05/2014
Date Insider Type Main position Quantity % Market Cap.
06/07Fiscal year

Chief Technology Officer

36,906 0.0170%
25/06Fiscal year

Chief Executive Officer

64,194 0.0296%
23/06Free

SVP, GM, Global Respiratory

19,912 0.0092%
Change 5-day change 1-year change 3-year change Capi.($)
-2.24%+3.59%+19.60%+466.72% 2.56TCr
-4.14%-8.06%+57.35%+117.24% 5.7TCr
+1.84%-0.66%+75.79%+93.87% 5.36TCr
-1.60%-6.21%-19.69%-14.84% 2.35TCr
+2.43%+1.06%+47.70%-0.11% 1.94TCr
-3.19%0.00%+33.99%-26.87% 1.81TCr
-6.84%+2.18%+195.12%+357.18% 1.65TCr
-1.05%+1.16%+25.08%+196.28% 1.44TCr
+8.74%+3.51%+53.81% - 1.41TCr
-4.16%+1.63%+70.58%+143.85% 1.29TCr
Average -1.02%+0.40%+55.93%+148.15% 2.55TCr
Weighted average by Cap. -1.18%-0.97%+55.48%+138.55%

Financials

2026 *2027 *
Net sales 168.75Cr 147.6Cr 136.15Cr 125.74Cr 238.6Cr 16TCr 242.61Cr 1.63TCr 638.81Cr 7.93TCr 633.6Cr 619.81Cr 27TCr 273.49Cr 239.22Cr 220.65Cr 203.79Cr 386.69Cr 26TCr 393.2Cr 2.64TCr 1.04TCr 13TCr 1.03TCr 1TCr 44TCr
Net income -57Cr -50Cr -46Cr -43Cr -81Cr -5.44TCr -82Cr -549.95Cr -215.97Cr -2.68TCr -214.21Cr -209.54Cr -9.21TCr 7.24Cr 6.33Cr 5.84Cr 5.4Cr 10Cr 690.69Cr 10Cr 70Cr 27Cr 340.25Cr 27Cr 27Cr 1.17TCr
Net Debt -57Cr -49Cr -46Cr -42Cr -80Cr -5.39TCr -81Cr -545.14Cr -214.08Cr -2.66TCr -212.33Cr -207.71Cr -9.13TCr -98Cr -86Cr -79Cr -73Cr -139Cr -9.38TCr -141.34Cr -947.7Cr -372.16Cr -4.62TCr -369.13Cr -361.09Cr -16TCr
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
10/26/10 $115.61 -2.24% 29,31,504
09/26/09 $118.26 +1.48% 31,67,091
08/26/08 $116.53 +3.27% 28,35,056
07/26/07 $112.84 +1.17% 16,74,721
06/26/06 $111.54 -0.05% 22,32,435
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
115.61USD
Average target price
197.05USD
Spread / Average Target
+70.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock